British researchers say they are launching a research study in which healthy volunteers will be vaccinated with the corona virus to find out how much or how much energy is needed to infect a person. According to the AFP news agency, the study has been named 'The Human Challenge Program' in which Imperial College London is also participating as a partner. The researchers hope that this research will help prevent the spread of the corona virus, reduce its effects and deaths.
According to the researchers, this will be the first study of its kind in the world and the first phase will explore the possibility of volunteers being exposed to the SARS Cove 2 Corona virus. The study will look at healthy volunteers between the ages of 18 and 30 who do not have heart disease, diabetes or obesity.
A statement from Imperial College stated that "in the early stages, the goal is to determine the minimum amount of virus that can cause a person to develop a code 19 infection."Peter Opinsha, a professor of experimental medicine at Imperial College, said the virus would be transmitted to volunteers through the nose.
"The biggest benefit of this research is that we will be able to see the volunteers up close at every stage," he said. Not only during the infection but also before and at every stage of the changes that can be analyzed. Researchers will be able to use the results of this research to discover the effects of vaccines and treatment methods.
The researchers said that because the volunteers would be infected with the virus themselves, it would be possible for scientists to see if the volunteers who were vaccinated were protected from the virus or if the effects of the virus on them were minimal. "Our first priority will be the safety of volunteers," said Chris Chew, a professor of infectious diseases at Imperial College.
"None of the research is risk-free, but the program will do its best to minimize the risk," he said.Professor Chris Chew said the research program would help save people in the UK and around the world from the epidemic. The research will begin early next year and is partnered by the government, a clinical company and a hospital.
